Astellas Pharma Inc (ALPMF) 15.1500 $ALPMF
Astellas Pharma Launches the Newest Element in its Global Corporate Brand Campaign On CNN's Global Broadcast Network
PR Newswire - Fri Feb 13, 8:00AM CST
Astellas Pharma Inc. (hereafter called Astellas or "the Company"
President and CEO, Yoshihiko Hatanaka, announces the newest element of its on-going rollout of the Company's global corporate brand campaign which will broadcast over CNN's worldwide network beginning Monday, Feb. 16, 2015.
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
High Triglyceridemia Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Mon Feb 09, 7:32AM CST
The report "High Triglyceridemia - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for High Triglyceridemia. Triglycerides are the most ordinary form of fat in the body. Triglycerides are the main component in vegetable oils and animal fats. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/high-triglyc...eport.html.
ISIS: 63.86 (-0.43), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Merus Labs Appoints Geoff Morrow as Vice President, Business Development
Marketwired - Wed Feb 04, 7:03AM CST
Merus Labs International Inc. (TSX: MSL)(NASDAQ: MSLI) ("Merus" or "the Company" today announced the appointment of Geoff Morrow as Vice President, Business Development.
MSL.TO: 2.43 (+0.13), MSLI: 1.96 (+0.08)
Astellas Pharma's (ALPMF) CEO Yoshihiko Hatanaka on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 02, 3:14PM CST
Mid Atlantic Bio Angels Portfolio Company Reaches Key Milestone
GlobeNewswire - Mon Feb 02, 9:43AM CST
Mid-Atlantic Bio Angels (MABA) announces today that Immunomic Therapeutics, Inc. (Immunomic), a company that obtained early investment from MABA members, has inked an exclusive licensing deal for Japan with Astellas Pharma Inc. to develop and commercialize a vaccine for Japanese Red Cedar Pollinosis. The deal could result in as much as $70 million for Immunomic in up front, milestone, and other payments and also provides for tiered double-digit royalties on net sales. This is an important milestone in the evolution of Immunomic, reflecting a significant increase in company value since the MABA members' investment.
Astellas Broadens Commitment to Clinical Trial Data Transparency
PR Newswire - Mon Feb 02, 8:00AM CST
Astellas Pharma Inc. (Tokyo: 4503, "Astellas" announced today that the company will now make trial data available through www.clinicalstudydatarequest.com, an independent Web site that enables researchers to request and access clinical trial data after approval of a research proposal by an independent review panel.
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Cedar Pollinosis
PR Newswire - Thu Jan 29, 6:00PM CST
Immunomic Therapeutics, Inc. ("Immunomic Therapeutics" , a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas" today announced they have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics' vaccine designed to treat allergies induced by Japanese red cedar pollen. The companies expect to initiate a Phase 1 trial of JRC2-LAMP-vax in Japan as soon as it is ready.
Franchise Fortunes Mark Shifts In Consensus For Marketed Products
EP Vantage - Seeking Alpha - Thu Jan 29, 3:48PM CST
Sofosbuvir is the gift that keeps on giving for Gilead Sciences (NASDAQ: GILD ). The performance of the hepatitis C franchise it has built around Sovaldi and Harvoni has had euphoric sell-side analysts giving it the biggest upgrade of any marketed...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), SNY: 49.42 (+0.82)
Constipation Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 10:30AM CST
The report "Constipation - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Constipation. Constipation is a disorder in which a person has severe problems defecating. Constipation occurs primarily because of the lack of the bowel movement in the body. The Lack of bowel movement in the body results in hardening of stools, swollen abdomen or abdominal pain. The reasons for constipation to occur in a body are inadequate water intake, less proportion of fiber in diet, irregularities in the pattern of diet. Not maintaining proper health and inadequacy in exercise can also lead to the abnormality during defecation & would mostly end with painful symptoms. Complete Report is Available @ http://www.rnrmarketresearch.com/constipation...eport.html .
SGYP: 2.98 (unch), SHPG: 239.82 (+6.11), AZN: 69.96 (+0.20), SCMP: 15.32 (+0.04), TEVA: 56.77 (-0.58)
Ad Comm gives thumbs up to Astellas anti-fungal
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 2:13PM CST
Ad Comm meets today to review Astellas NDA for antifungal med
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 7:51AM CST
Xtandi successful in Phase 2 study
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 7:34AM CST
MDVN: 104.71 (+0.67), AZN: 69.96 (+0.20)
Astellas' Isavuconazonium Should Pass Ad Comm Meeting For 2 Indications
Clinically Sound Investor - at Seeking Alpha - Wed Jan 21, 7:39AM CST
Boehringer Ingelheim's OFEV cleared in Europe for IPF
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:26PM CST
AZN: 69.96 (+0.20), FGEN: 30.25 (+0.50), BMY: 60.04 (+0.56)
Dermatitis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014-2015
M2 - Fri Jan 16, 5:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/449cq9/dermatitis_market) has announced the addition of the "Dermatitis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Dermatitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Astellas Pharma US, Inc. - Horizon Pharma, Inc. - Quinnova Pharmaceuticals, Inc. - Merck & Co., Inc. - Bayer HealthCare Pharmaceuticals Inc. - Stiefel Laboratories, Inc. - AbbVie Inc. - Pfizer Inc. - Pharmacia & Upjohn, Inc. - Roxane Laboratories, Inc. - PharmaDerm - Prestium Pharma, Inc. - Aqua Pharmaceuticals, LLC - Lilly USA, LLC - Novartis Pharmaceuticals Corporation - Astellas Pharma Inc. - Organon USA Inc. - Apothecon Inc - Schering-Plough HealthCare Products, Inc - Schering-Plough Corporation (Inactive) - Taro Pharmaceutical Industries Ltd. - Merck Sharp & Dohme Corp. - Onset Dermatologics - Standard Homeopathic Company - Sandoz Inc. - Panray Corporation - UCB, Inc. - Concordia Pharmaceuticals Inc. - Medimetriks Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/44...tis_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 229.49 (+1.87), TARO: 161.14 (-1.44), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), HZNP: 16.84 (-0.41), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17)
Astellas Pharma Inc. Hires Global Executive Eric Terhaerdt to Lead Global Development Operations
PR Newswire - Thu Jan 15, 5:00AM CST
Astellas Pharma Inc. ("Astellas," Tokyo: 4503) today announced that Eric Terhaerdt has been named senior vice president of Global Development Operations. Terhaerdt will be located at Astellas' Headquarters for the Americas in Northbrook, Ill., USA, and will report to Dr. Bernie Zeiher, executive vice president, Global Development and Therapeutic Area head: Immunology, Infectious Disease, Transplantation and Central Nervous System and Pain, with Astellas Pharma Global Development, Inc.
Astellas Pharma Launches the Newest Element in its Global Corporate Brand Campaign On CNN's Global Broadcast Network
PR Newswire - Fri Feb 13, 8:00AM CST
Astellas Pharma Inc. (hereafter called Astellas or "the Company"
President and CEO, Yoshihiko Hatanaka, announces the newest element of its on-going rollout of the Company's global corporate brand campaign which will broadcast over CNN's worldwide network beginning Monday, Feb. 16, 2015. Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
High Triglyceridemia Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Mon Feb 09, 7:32AM CST
The report "High Triglyceridemia - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for High Triglyceridemia. Triglycerides are the most ordinary form of fat in the body. Triglycerides are the main component in vegetable oils and animal fats. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/high-triglyc...eport.html.
ISIS: 63.86 (-0.43), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Merus Labs Appoints Geoff Morrow as Vice President, Business Development
Marketwired - Wed Feb 04, 7:03AM CST
Merus Labs International Inc. (TSX: MSL)(NASDAQ: MSLI) ("Merus" or "the Company"
today announced the appointment of Geoff Morrow as Vice President, Business Development. MSL.TO: 2.43 (+0.13), MSLI: 1.96 (+0.08)
Astellas Pharma's (ALPMF) CEO Yoshihiko Hatanaka on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 02, 3:14PM CST
Mid Atlantic Bio Angels Portfolio Company Reaches Key Milestone
GlobeNewswire - Mon Feb 02, 9:43AM CST
Mid-Atlantic Bio Angels (MABA) announces today that Immunomic Therapeutics, Inc. (Immunomic), a company that obtained early investment from MABA members, has inked an exclusive licensing deal for Japan with Astellas Pharma Inc. to develop and commercialize a vaccine for Japanese Red Cedar Pollinosis. The deal could result in as much as $70 million for Immunomic in up front, milestone, and other payments and also provides for tiered double-digit royalties on net sales. This is an important milestone in the evolution of Immunomic, reflecting a significant increase in company value since the MABA members' investment.
Astellas Broadens Commitment to Clinical Trial Data Transparency
PR Newswire - Mon Feb 02, 8:00AM CST
Astellas Pharma Inc. (Tokyo: 4503, "Astellas"
announced today that the company will now make trial data available through www.clinicalstudydatarequest.com, an independent Web site that enables researchers to request and access clinical trial data after approval of a research proposal by an independent review panel. Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Cedar Pollinosis
PR Newswire - Thu Jan 29, 6:00PM CST
Immunomic Therapeutics, Inc. ("Immunomic Therapeutics"
, a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas" today announced they have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics' vaccine designed to treat allergies induced by Japanese red cedar pollen. The companies expect to initiate a Phase 1 trial of JRC2-LAMP-vax in Japan as soon as it is ready. Franchise Fortunes Mark Shifts In Consensus For Marketed Products
EP Vantage - Seeking Alpha - Thu Jan 29, 3:48PM CST
Sofosbuvir is the gift that keeps on giving for Gilead Sciences (NASDAQ: GILD ). The performance of the hepatitis C franchise it has built around Sovaldi and Harvoni has had euphoric sell-side analysts giving it the biggest upgrade of any marketed...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), SNY: 49.42 (+0.82)
Constipation Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 10:30AM CST
The report "Constipation - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Constipation. Constipation is a disorder in which a person has severe problems defecating. Constipation occurs primarily because of the lack of the bowel movement in the body. The Lack of bowel movement in the body results in hardening of stools, swollen abdomen or abdominal pain. The reasons for constipation to occur in a body are inadequate water intake, less proportion of fiber in diet, irregularities in the pattern of diet. Not maintaining proper health and inadequacy in exercise can also lead to the abnormality during defecation & would mostly end with painful symptoms. Complete Report is Available @ http://www.rnrmarketresearch.com/constipation...eport.html .
SGYP: 2.98 (unch), SHPG: 239.82 (+6.11), AZN: 69.96 (+0.20), SCMP: 15.32 (+0.04), TEVA: 56.77 (-0.58)
Ad Comm gives thumbs up to Astellas anti-fungal
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 2:13PM CST
Ad Comm meets today to review Astellas NDA for antifungal med
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 7:51AM CST
Xtandi successful in Phase 2 study
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 7:34AM CST
MDVN: 104.71 (+0.67), AZN: 69.96 (+0.20)
Astellas' Isavuconazonium Should Pass Ad Comm Meeting For 2 Indications
Clinically Sound Investor - at Seeking Alpha - Wed Jan 21, 7:39AM CST
Boehringer Ingelheim's OFEV cleared in Europe for IPF
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:26PM CST
AZN: 69.96 (+0.20), FGEN: 30.25 (+0.50), BMY: 60.04 (+0.56)
Dermatitis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014-2015
M2 - Fri Jan 16, 5:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/449cq9/dermatitis_market) has announced the addition of the "Dermatitis Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Dermatitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Astellas Pharma US, Inc. - Horizon Pharma, Inc. - Quinnova Pharmaceuticals, Inc. - Merck & Co., Inc. - Bayer HealthCare Pharmaceuticals Inc. - Stiefel Laboratories, Inc. - AbbVie Inc. - Pfizer Inc. - Pharmacia & Upjohn, Inc. - Roxane Laboratories, Inc. - PharmaDerm - Prestium Pharma, Inc. - Aqua Pharmaceuticals, LLC - Lilly USA, LLC - Novartis Pharmaceuticals Corporation - Astellas Pharma Inc. - Organon USA Inc. - Apothecon Inc - Schering-Plough HealthCare Products, Inc - Schering-Plough Corporation (Inactive) - Taro Pharmaceutical Industries Ltd. - Merck Sharp & Dohme Corp. - Onset Dermatologics - Standard Homeopathic Company - Sandoz Inc. - Panray Corporation - UCB, Inc. - Concordia Pharmaceuticals Inc. - Medimetriks Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/44...tis_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 229.49 (+1.87), TARO: 161.14 (-1.44), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), HZNP: 16.84 (-0.41), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17)
Astellas Pharma Inc. Hires Global Executive Eric Terhaerdt to Lead Global Development Operations
PR Newswire - Thu Jan 15, 5:00AM CST
Astellas Pharma Inc. ("Astellas," Tokyo: 4503) today announced that Eric Terhaerdt has been named senior vice president of Global Development Operations. Terhaerdt will be located at Astellas' Headquarters for the Americas in Northbrook, Ill., USA, and will report to Dr. Bernie Zeiher, executive vice president, Global Development and Therapeutic Area head: Immunology, Infectious Disease, Transplantation and Central Nervous System and Pain, with Astellas Pharma Global Development, Inc.
